BGB 15025|CAS 2766481-17-6|DC Chemicals

Cas No.:	2766481-17-6
Chemical Name:	Benzamide, 4-[5-amino-6-[[1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]oxy]-2-pyrazinyl]-N-[2-[(3R)-3-fluoro-1-pyrrolidinyl]ethyl]-2,6-dimethyl-
Synonyms:	Benzamide, 4-[5-amino-6-[[1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]oxy]-2-pyrazinyl]-N-[2-[(3R)-3-fluoro-1-pyrrolidinyl]ethyl]-2,6-dimethyl-;BGB-15025
SMILES:	C1CN(C)CCC1N1C=C(OC2N=C(C3=CC(C)=C(C(NCCN4CC[C@@H](F)C4)=O)C(C)=C3)C=NC=2N)C=N1
Formula:	C₂₈H₃₇FN₈O₂
M.Wt:	536.64
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	BGB-15025 is a potent and selective HPK1 inhibitor. It is used in the treatment of various cancers.
Target:	HPK1
In Vitro:	HPK1-IN-32 (Example A34, 0-2 μM, 2 h) inhibits pSLP76 activity in Jurkat cells with an IC50 of 65 nM [1].
References:	[1]. Sanjia XU, et al. 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof. Patent. WO2022068848.

Cat. No.	Product name	Field of application
DC74333	BAY-405	BAY-405 is a potent and selective MAP4K1 inhibitor with IC50 of 6 nM. BAY-405 potentiates in vitro and in vivo antitumor T-cell reactivity which overcomes the suppression by TGFβ and PGE2.
DC72741	BGB 15025	BGB-15025 is a potent and selective HPK1 inhibitor. It is used in the treatment of various cancers.
DC46921	HPK1-IN-7	HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.